Kallikrein-Targeted Binding Agents for Disseminated Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for prostate cancer, particularly in cases of disseminated disease and micrometastases, are inadequate, necessitating the development of new therapeutic agents and methods for effective treatment.
Innovation Solution
The use of a binding moiety with specificity for kallikrein proteins, such as PSA or hK2, to target and treat prostate cancer, utilizing agents like antibodies, aptamers, or small chemical entities that selectively bind to these proteins, potentially combined with therapeutic moieties for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies (surgery, radiation, chemotherapy, hormonal therapy) are used to treat prostate cancer, then primary tumors and large metastases can be treated, but disseminated disease and micrometastases remain difficult to effectively treat
Solution Approach 1:
The invention changes the parameter of therapeutic approach from non-specific conventional therapies to specific targeted therapy. By using binding moieties that specifically recognize and bind to kallikrein proteins (PSA, hK2) expressed on cancer cells, the therapy becomes adaptable to different stages and types of prostate cancer, particularly effective against micrometastases and disseminated disease where conventional therapies fail.
Solution Approach 2:
The invention introduces binding moieties (antibodies, aptamers, or small chemical entities) as intermediary agents between the therapeutic effect and the cancer cells. These intermediaries specifically target kallikrein proteins on the cell surface, enabling selective delivery of therapeutic action to cancer cells while sparing normal tissue, thus improving reliability for disseminated disease treatment.
2Reliability
If binding moieties with specificity for kallikrein proteins are used, then targeted therapy and therapeutic ratio are improved, but development complexity increases
Solution Approach 1:
The invention applies universality by developing binding moieties that can target multiple kallikrein proteins (PSA, hK2) and potentially multiple cancer cell types. This multi-functional approach improves therapeutic ratio by covering various forms of prostate cancer while managing development complexity through a unified targeting strategy rather than requiring separate therapies for each cancer type.
Solution Approach 2:
The invention uses copying by employing multiple types of binding moieties (antibodies, aptamers, small chemical entities) that replicate the function of targeting kallikrein proteins. This allows the same therapeutic effect to be achieved through different molecular mechanisms, improving reliability while distributing development complexity across multiple accessible platforms rather than requiring invention of entirely new therapeutic classes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The binding moieties effectively target and inhibit kallikrein proteins, offering a promising approach for treating prostate cancer, especially in disseminated and micrometastatic cases, with potential for improved therapeutic ratios and tumor uptake characteristics.
Implementation Method 1
a binding moiety with specificity for a kallikrein protein
Data Source
AI summary
The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.